Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer

OncoImmunology

Volumn 6, Issue 4, 2017, Pages

  Zhou, Lin ^a   Xu, Le ^b   Chen, Lingli ^a   Fu, Qiang ^a   Liu, Zheng ^a   Chang, Yuan ^a   Lin, Zongming ^a   Xu, Jiejie ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adjuvant chemotherapy; bladder cancer; overall survival; prognosis; tumor infiltrating neutrophil

Indexed keywords

CISPLATIN; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; DOXORUBICIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 8; METHOTREXATE; VINBLASTINE;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER STAGING; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE INVASIVE BLADDER CANCER; NEUTROPHIL; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 85017147250     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1293211     Document Type: Article

References (43)

1. Dvorak HF, Flier J, Frank H. Tumors - wounds that do not heal - similarities between tumor stroma generation and wound-healing. N Engl J Med 1986; 315:1650-9; PMID:3537791; http://dx.doi.org/10.1056/NEJM198612253152606
2. Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A,; European Association of Urology. EAU guidelines on muscle-invasive and metastatic bladder cancer:summary of the 2013 guidelines. Euro Urol 2014; 65:778-92; PMID:24373477; http://dx,.doi.org/10.1016/j.eururo.2013.11.046
3. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ, Sr, Trump D. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma:A cooperative group study. J Clin Oncol 1997; 15:2564-9; PMID:9215826
4. Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van Groeningen CJ, Duclos B, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Euro J Cancer 2006; 42:50-4; PMID:16330205; http://dx.doi.org/10.1016/j.ejca.2005.08.032
5. Bono AV, Goebell PJ, Groshen S, Lehmann J, Studer U, Torti FM, et al. Adjuvant chemotherapy in invasive bladder cancer:A systematic review and meta-analysis of individual patient data. Euro Urol 2005; 48:189-201; PMID:15939530; http://dx.doi.org/10.1016/j.eururo.2005.04.005
6. Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, et al. Adjuvant Chemotherapy for Invasive Bladder Cancer:A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials. Euro Urol 2014; 66:42-54; PMID:24018020; http://dx.doi.org/10.1016/j.eururo.2013.08.033
7. Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer:neutral no more. Nat Rev Cancer 2016; 16:431-46; PMID:27282249; http://dx.doi.org/10.1038/nrc.2016.52
8. Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016; 7:12150-; PMID:27381735; http://dx.doi.org/10.1038/ncomms12150
9. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175
10. Fridlender ZG, Albelda SM. Tumor-associated neutrophils:friend or foe? Carcinogenesis 2012; 33:949-55; PMID:22425643; http://dx.doi.org/10.1093/carcin/bgs123
11. Shen M, Hu P, Donskov F, Wang G, Liu Q, Du J. Tumor-associated neutrophils as a new prognostic factor in cancer:a systematic review and meta-analysis. Plos One 2014; 9:e98259; PMID:24906014; http://dx.doi.org/10.1371/journal.pone.0098259
12. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-beta:“N1” versus “N2” TAN. Cancer Cell 2009; 16:183-94; PMID:19732719; http://dx.doi.org/10.1016/j.ccr.2009.06.017
13. Sagiv JY, Michaeli J, Assi S, Mishalian I, Kisos H, Levy L, Damti P, Lumbroso D, Polyansky L, Sionov RV, et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell Rep 2015; 10:562-73; PMID:25620698; http://dx.doi.org/10.1016/j.celrep.2014.12.039
14. Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson AA, Wauters E, Walmsley S, Prenen H, Granot Z, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature 2015; 522:349-53; PMID:25985180; http://dx.doi.org/10.1038/nature14407
15. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 2006; 103:12493-8; PMID:16891410; http://dx.doi.org/10.1073/pnas.0601807103
16. Shojaei F, Singh M, Thompson JD, Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A 2008; 105:2640-5; PMID:18268320; http://dx.doi.org/10.1073/pnas.0712185105
17. Katoh H, Wang D, Daikoku T, Sun H, Dey SK, DuBois RN. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell 2013; 24:631-44; PMID:24229710; http://dx.doi.org/10.1016/j.ccr.2013.10.009
18. Newman AM, Liu CL, Green MR, Gentles AJ, Feng WG, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015; 12:453-7; PMID:25822800; http://dx.doi.org/10.1038/nmeth.3337
19. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 2011; 25:2465-79; PMID:9060447; http://dx.doi.org/10.1101/gad.180331.111
20. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54-67; PMID:22039576; http://dx.doi.org/10.1158/2159-8274.CD-10-0028
21. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, et al. A CXCL1 Paracrine network links cancer chemoresistance and metastasis. Cell 2012; 150:165-78; PMID:22770218; http://dx.doi.org/10.1016/j.cell.2012.04.042
22. Bellmunt J, Petrylak DP. New therapeutic challenges in advanced bladder cancer. Semin Oncol 2012; 39:598-607; PMID:23040256; http://dx.doi.org/10.1053/j.seminoncol.2012.08.007
23. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014; 25:152-65; PMID:24525232; http://dx.doi.org/10.1016/j.ccr.2014.01.009
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis:A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102:15545-50; PMID:16199517; http://dx.doi.org/10.1073/pnas.0506580102
25. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-95; PMID:24138885; http://dx.doi.org/10.1016/j.immuni.2013.10.003
26. Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10kD (IP-10):A novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997; 8:207-19; PMID:9462486; http://dx.doi.org/10.1016/S1359-6101(97)00015-4
27. Farber JM. Mig and IP-10:CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61:246-57; PMID:9060447
28. Sobin LH, et al. TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edn. 2009, Oxford.
29. Bindea G, Mlecnik B, Fridman W-H, Pages F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol 2010; 22:215-22; PMID:20207124; http://dx.doi.org/10.1016/j.coi.2010.02.006
30. Kawahara T, Furuya K, Nakamura M, Sakamaki K, Osaka K, Ito H, Ito Y, Izumi K, Ohtake S, Miyoshi Y, et al. Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy. Bmc Cancer 2016; 16:185; PMID:26944862; http://dx.doi.org/10.1186/s12885-016-2219-z
31. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies:reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
32. Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy:harnessing potential synergies. Cancer Immunol Res 2015; 3:436-43; PMID:25941355; http://dx.doi.org/10.1158/2326-6066.CIR-15-0064
33. Cook AM, Lesterhuis WJ, Nowak AK, Lake RA. Chemotherapy and immunotherapy:mapping the road ahead. Curr Opin Immunol 2016; 39:23-9; PMID:26724433; http://dx.doi.org/10.1016/j.coi.2015.12.003
34. Sceneay J, Chow MT, Chen A, Halse HM, Wong CSF, Andrews DM, Sloan EK, Parker BS, Bowtell DD, Smyth MJ, et al. Primary tumor hypoxia recruits CD11b(+)/Ly6C(med)/Ly6G(+) immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res 2012; 72:3906-11; PMID:22751463; http://dx.doi.org/10.1158/0008-5472.CAN-11-3873
35. Spiegel A, Brooks MW, Houshyar S, Reinhardt F, Ardolino M, Fessler E, Chen MB, Krall JA, DeCock J, Zervantonakis IK, et al. Neutrophils suppress intraluminal NK cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells. Cancer Discov 2016; 6:630-49; PMID:27072748; http://dx.doi.org/10.1158/2159-8290.CD-15-1157
36. Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, Fan J, Cao Y, Dai Z, Zhou J. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. Gastroenterology 2016; 150:1646-58; PMID:26924089; http://dx.doi.org/10.1053/j.gastro.2016.02.040
37. Sauter G AF, Amin M, et al. Tumours of the urinary system:non-invasive urothelial neoplasias. In:Eble JN, Sauter G, Epstein Jl, et al. (eds). WHO classification of classification of tumors of the urinary system and male genital organs. Lyon:IARCC Press, 2004:29-34
38. Sobin LH GM, Wittekind C, editors. TNM classification of malignant tumors. ed. 7. Hoboken, NJ:Wiley-Blackwell; 2009:262-5
39. Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, McConkey D, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507:315-22; http://dx.doi.org/10.1038/nature12965
40. Budczies J, Klauschen F, Sinn BV, Gyoerffy B, Schmitt WD, Darb-Esfahani S, Denkert C. Cutoff Finder:A comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. Plos One 2012; 7:e51862; PMID:23251644; http://dx.doi.org/10.1371/journal.pone.0051862
41. Xu L, Zhu Y, An H, Liu Y, Lin Z, Wang G, Xu J. Clinical significance of tumor-derived IL-1beta and IL-18 in localized renal cell carcinoma:Associations with recurrence and survival. Urol Oncol 2015; 33:68.e9-16; PMID:25241276; http://dx.doi.org/10.1016/j.urolonc.2014.08.008
42. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1 alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34:267-73; PMID:12808457; http://dx.doi.org/10.1038/ng1180
43. Robinson MD, McCarthy DJ, Smyth GK. edgeR:A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010; 26:139-40; PMID:19910308; http://dx.doi.org/10.1093/bioinformatics/btp616